Intercept Pharmaceuticals‘ (ICPT) fell more than 15% in premarket trade Wednesday, after the company announced results of a 72-week Phase 2 trial of obeticholic acid, its treatment for adults in Japan with liver inflammation (or, nonalcoholic steatohepatitis). The company said the treatment reached the desired results for some patients, but not so much for others. […] View the full post at: Morning Buzz: Intercept Pharma (ICPT), Cabela’s Inc (CAB), Apple (AAPL), Twitter (TWTR) Related posts: Carl Icahn Lowers Stake in Yahoo! to 4.48% Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock Icahn Discloses Position in CIT Group